VIFOR PHARMA REPORTS STRONG H1 2017 RESULTS AND RAISES GUIDANCE
- Strong financial performance in H1 2017
- Three medium-term strategic growth drivers on track
- Milestone 2020 strategic plan initiated
- Two strategic in-licensing deals and one strategic out-licensing deal concluded
- Net sales and EBITDA guidance for 2017 raised and positive outlook confirmed
IN H1 2017, VIFOR PHARMA RECORDED A STRONG FINANCIAL PERFORMANCE DRIVEN BY ITS THREE MEDIUM-TERM STRATEGIC GROWTH DRIVERS. THE COMPANY ALSO SUCCESSFULLY INITIATED ITS MILESTONE 2020 STRATEGIC PLAN AND CONCLUDED THREE NEW STRATEGIC LICENSING DEALS. AS A RESULT OF THE STRONG H1 2017 FINANCIAL PERFORMANCE THE COMPANY IS RAISING ITS NET SALES AND EBITDA GUIDANCE FOR 2017 AND CONFIRMING THE POSITIVE OUTLOOK.
VIFOR PHARMA GROUP FINANCIAL PERFORMANCE
|in million CHF|| H1 |
| H1 |
| Change |
|EBITDA excluding launch and ramp-up of Veltassa®||252.3||209.9||20.2|
|Cash net of debt||140.5||-1,832.11)||n/a|
|Net profit after minorities||1,093.7||158.9||588.3|
|Core earnings per share||0.61||2.0||-69.7|
For further details, please see the Vifor Pharma Group 2017 Half-year Report (PDF only) at www.viforpharma.com.
1) As of year-end 2016
| Media Relations |
Head of Global Communications & Public Affairs
Tel.: +41 58 851 80 16
| Investor Relations |
Head of Investor Relations
Tel.: +41 58 851 66 90
Vifor Pharma Group, formerly Galenica Group, is a global specialty pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for specialty pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical Care; Relypsa; and OM Pharma. Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit www.viforpharma.com.